|
4th International AIDS Society Conference on HIV Pathogenesis and TreatmentSydney, Australia - July 22 - 25, 2007 |
OPIOID SUBSTITUTION THERAPY (OST) WITH BUPRENORPHINE IN UKRAINE – WAY TO PREVENT HIV/AIDS AMONG IDUs
IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOAC204
Dvoriak S.
Ukrainian Institute on Public Health Policy, Research, Kyiv, Ukraine
OBJECTIVES: Ukraine still is an epicenter of HIV epidemic in Eastern Europe. IDUs accounts for 70% of HIV cases. OST was unavailable in Ukraine until 2004 and still is at issue. Buprenorphine is only medication which available for OST in the country.
The purpose of the study to confirm an idea that OST is effective measure for HIV prevention and expansion of ARV therapy among IDUs.
METHODS: The National buprenorphine maintenance therapy project began in October 2005 and this study details lessons learned over the first 16 months. There are 525 patients on BMT. Approximately 65% are HIV-infected with approximately 25% of them on ARVs. Addiction Severity Index (ASI), Blood Born Virus Assessment Questionnaires (BBV-Traq) and WHO Qality of Life Questionnaire were used for evaluation of effectiveness of treatment.
RESULTS: It was proved BMT improves retention in drug treatment and linkage to health care to improve overall health outcomes. After 6 months, retention is approximately 70%. Average score of drug use by ASI at baseline was 0.3238±0.1208 and in 6 months – 0.0944±0.0866. Injection behavior according to BBV-Traq at baseline was – 12,8±14,5 and in 6 month 0,7±4,9. Additionally, clients have experienced other personal successes: weight gain, improvements in interpersonal relationships, obtaining and keeping employment.
Individuals on ARV-therapy demonstrated higher level of retention in BMT. There were no remarkable interactions between ARV medications and buprenorphine.
CONCLUSIONS: BMT in Ukraine, with high levels of retention in treatment and dramatic decreasing of injection behavior, remains promising. There is obvious necessity for expansion of OST to allow GPs to be allowed to prescribe buprenorphine. Additionally, the availability of methadone must be addressed. Both are desperately needed if OST is to expand from 525 to 6,000 by the end of 2007 and, most importantly, the estimated goal of 60,000 necessary to impact the HIV epidemic in Ukraine.
Download PDF of this abstract.
2007-07-22
MOAC204
Global Responses to HIV Prevention Among Injection Drug Users
Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.